Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05487612 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

MiECC Versus Conventional Cardiopulmonary Bypass in Cardiac Surgery (MiECS)

Study acronym: MiECS
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Dec 31, 2026 to Dec 31, 2028
    • Study sites: 12 to 13
    • Study completion date: Mar 31, 2027 to Mar 31, 2029
    v4
  2. Primary completion date: Dec 31, 2025 to Dec 31, 2026v3 Show 4 more changesShow less
    • Study sites: 13 to 12
    • Study completion date: Mar 31, 2026 to Mar 31, 2027
    • Collaborators expanded, about 7 words
    • Publications: details revised at 1 of 8 entries
  3. Secondary endpoints revised (13)v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
MiECS is one of the largest multicentre randomised controlled trials on extracorporeal circulation conducted under the auspices of Minimal Invasive Extracorporeal Technologies International Society (MiECTiS). It is designed to ultimately address the emerging effectiveness of MiECC systems in the light of modern perfusion practice worldwide. The primary hypothesis is that MiECC, as compared to conventional CPB (cCPB), reduces the proportion of patients experiencing serious perfusion-related postoperative morbidity after cardiac surgery. The study will be led by the Clinical Research Unit of the Special Unit for Biomedical Research and Education (SUBRE), Aristotle University of Thessaloniki School of Medicine in Greece (AUSoM) with Chief Investigator Professor Kyriakos Anastasiadis, who is a key-opinion-leader in the field of MiECC, founder and Executive Board of MiECTiS.
Trial Details
NCT Number NCT05487612
Lead Sponsor Aristotle University Of Thessaloniki
Collaborators: Minimal Invasive Extracorporeal Technologies International Society (MiECTiS)
Conditions
(from sponsor)		 Coronary Artery Disease, Aortic Valve Stenosis, Extracorporeal Circulation; Complications
Related terms Aortic Valve Stenosis, Coronary Artery Disease
Enrollment 1,300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov